If you enjoy this content, please share it with a colleague
Devicor Medical Products Inc.
RELATED CONTENT
GTCR, a private equity firm, announced Devicor Medical Products has signed an agreement to be acquired by Danaher Corp.’s Leica Biosystems, a provider of anatomical pathology solutions and automation used to advance cancer diagnostics.
Devicor Medical Products Inc. acquired HydroMARK breast biopsy marker portfolio and related assets from Biopsy Sciences LLC.
December 11, 2012 — Devicor Medical Products Inc. (Devicor) announced that the U.S. Food and Drug Administration (FDA) has approved Mammotome revolve, a dual vacuum-assisted biopsy system, for use on patients.
April 26, 2012 — Devicor Medical Products Inc. announced the commercial launch of the Mammotome elite Biopsy System, the only tetherless single insertion, multiple sample, vacuum-assisted biopsy (VAB) device featuring proprietary TruVac vacuum technology.
March 15, 2012 — Devicor Medical Products Inc. announced that it signed a distribution agreement with Carbon Medical Technologies Inc.
August 22, 2011 – Devicor Medical Products Inc. announced the completion of its previously discussed agreement to acquire the neoprobe gamma detection system (GDS) products and related assets from Neoprobe Corporation.
May 26, 2011 -- Devicor Medical Products Inc., announced it has signed an asset purchase agreement with Neoprobe Corporation to acquire the Neoprobe GDS portfolio of products. Devicor currently provides distribution and marketing services to Neoprobe for the gamma detection systems covered by this agreement.
December 22, 2010 – The Mammotome molecular imaging (MI) system, which is used to conduct minimally invasive, vacuum-assisted breast biopsy (VABB) with molecular imaging guidance, has received 510(k) clearance. It is the first device of its kind to receive FDA clearance, and it is commercially available to healthcare facilities specializing in breast cancer screening and diagnosis.